Pricing Log in Create free account
Friday 6 November 2026 Export PAVM’s income statement to Excel — free account

PAVmed Inc.

PAVM Healthcare Medical Devices

PAVmed Inc.’s revenue for fiscal 2025 (year ended December 2025) was $71,000.00, down 97.6% from fiscal 2024.

Revenue
+450.0%
EPS
+96.1%
Free cash flow
−125.6%

Quarter to June 2026, against a year earlier

1.57 0.02 +1.29%
Market cap
$12.4M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
2/9
Altman Z
−11.40
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 33.81%

Capital & Financial Ratios $m

Size
Market Cap 12.39
Revenue ttm 0.11
Net income ttm (16.43)
Free cash flow ttm (7.78)
Net debt Q 11.32
Valuation
P/E 0.00
Forward P/E (0.54) (negative: loss-making)
Price / sales 87.88 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.64
Financial health
Current ratio Q 1.19
Debt / equity Q 0.78
Interest coverage Q (3,511.00)
Growth
Revenue growth Q +450.00% (above 0%: growing)
Operating income growth Q −48.93% (below 0%: shrinking)
EPS, this year +35.70% (at or above 15%: strong)
EPS, next year A +45.30% (at or above 15%: strong)
Revenue, next year A +227.46% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +59.25% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 189×, against a ten-year median of 3.7×; over the ten years it ranged from −21.9× in 2022 to 434× in 2026.
P/S against its own 10 years 70.58%
10-year low 10-year high
P/B against its own 10 years 4.09%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 20 1 2 4
Receivables 0 0 0 0
Inventory 0 — — —
Other — — — —
24 2 3 5
2023 2024 2025 Q'26
Payables 2 1 1 1
ST’ Debt — — — —
Other — — — —
54 35 15 4

Compound Annual Growth %

10y 5y 3y
Sales — — (42.68%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 42.77% 0.00% 26.82%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.63 Actual −0.27

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −6.01 −8.41 Miss by 2.40
Q4 FY25 −4.50 −1.05 Beat by 3.45
Q1 FY26 −0.69 −1.17 Miss by 0.48
Q2 FY26 −0.63 −0.27 Beat by 0.36
Q3 FY26 −0.63 — Reports 13 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (4.42) (0.87) — — —
’25 10.21 (22.22) (8.71) (2.04) (5.63)
’24 (78.68) (35.74) 43.24 — 14.90
’23 (85.54) (63.03) (72.04) (59.46) (275.07)
’22 (90.04) (130.56) (130.56) (103.55) (450.22)
’21 (58.53) (63.03) (67.53) (90.04) (292.65)
’20 (148.57) (58.53) (49.52) (76.54) (328.66)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 0 0 0 0 0
’24 1 1 1 0 3
’23 0 0 1 1 2
’22 0 — 0 0 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (3) — — —
’25 (2) (1) (1) (2) (5)
’24 (13) (12) (9) 0 (34)
’23 (16) (13) (11) (12) (52)
’22 (12) (23) (19) (17) (71)
’21 (9) (7) (8) (17) (41)
’20 (4) (6) (6) (7) (22)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (3) — — —
’25 (2) (1) (1) (2) (5)
’24 (13) (12) (9) 0 (33)
’23 (15) (13) (11) (12) (51)
’22 (13) (23) (20) (17) (73)
’21 (9) (7) (8) (18) (42)
’20 (4) (6) (6) (7) (22)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — — — 1 0 2 3 0 0 (38.6%) 0 1 — +190.7%
Gross margin, % 0.00 0.00 0.00 0.00 0.00 (17.00) (858.62) (161.83) (61.60) (207.04) (221.43) (207.0) pt
EBT (6) (10) (18) (17) (36) (56) (103) (79) 28 (2) (16) (8.8%)
EBT margin, % 0.00 0.00 0.00 0.00 0.00 (11,225.20) (27,384.08) (3,232.59) 949.15 (3,477.46) (14,669.64) (3,477.5) pt
Net income (6) (10) (18) (17) (36) (56) (103) (79) 28 (2) (16) (8.8%)
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 0.00 2.90 1.91 10.18 9.29 0.11 0.02 n/m
Earnings (198.10) (346.67) (378.19) (247.62) (328.66) (292.65) (450.22) (275.07) 99.15 (5.63) (16.04) (32.7%)
Cash flow (154.68) (220.27) (177.53) (199.06) (207.91) (235.72) (359.05) (216.10) (104.08) (7.76) (1.23) (28.3%)
Capex (0.76) (0.18) (0.54) (0.40) (0.52) (8.53) (7.79) 3.15 0.92 (0.05) (0.01) (26.7%)
Free cash flow (155.44) (220.45) (178.07) (199.46) (208.43) (244.25) (366.84) (212.95) (103.16) (7.81) (1.24) (28.3%)
Book value (11.08) (94.95) (50.02) (69.12) (4.49) 461.20 55.31 (99.74) (21.81) 33.26 3.08 n/m
Shares, m 0 0 0 0 0 0 0 0 0 1 2 +41.9%
Valuation, ×
Valuation, × P/E — — — — — 0.00 0.00 0.00 0.23 1.25 0.00 0.3
P/S — — — — — 0.00 56.94 10.57 2.03 83.81 87.88 30.7
P/B — — — — — 2.19 4.68 0.00 0.00 0.00 0.64 1.4
EV/Sales — — — — — 0.00 0.96 3.93 2.75 109.24 188.92 23.4
EV/FCF — — — — — (2.49) (0.01) (0.19) (0.25) (1.59) (2.85) (0.9)
Cash, $m
Cash, $m Operating cash flow (4) (7) (9) (13) (22) (41) (71) (52) (34) (5) (8) +1.7%
Capex 0 0 0 0 0 (1) (2) 1 0 0 0 +4.0%
Free cash flow (4) (7) (9) (13) (22) (42) (73) (51) (33) (5) (8) +1.8%
Balance, $m
Balance, $m Working capital 0 (1) (3) (5) (1) 75 3 (30) (33) (12) 1 +44.5%
Net debt (1) 0 (8) (6) (17) (77) (40) (20) (1) (2) 11 +11.3%
Shareholders’ equity 0 (3) (2) (5) 0 79 11 (24) (7) 22 19 n/m
Returns, %
Returns, % ROA (542.18) (828.50) (369.98) (212.59) (255.85) (94.85) (126.66) (152.17) 100.24 (10.86) (49.05) +531.3 pt
ROIC 0.00 0.00 0.00 0.00 0.00 (1,573.87) 0.00 0.00 0.00 (65.64) (54.50) (65.6) pt
ROE (3,590.15) 495.14 447.03 292.38 695.15 (136.86) (209.45) 706.05 (171.12) 59.31 (216.61) +3,649.5 pt
People
People Employees 3 5 9 15 25 89 124 107 39 41 — +33.7%
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.02 0.08 0.00 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

PAVmed Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
RBOT Vicarious Surgical Inc. $14.3M — (loss-making) — — n/m +47.33% (above 0%: growing) 0.00% 0.00% Compare
HSCS HeartSciences Inc. $13.3M — (loss-making) — (loss-making) −46.15% (below 0%: shrinking) n/m +18.18% (above 0%: growing) 61.90% (139,957.14%) Compare
PETV PetVivo Holdings, Inc. $12.9M — (loss-making) — (loss-making) +13.48% (above 0%: growing) n/m +40.13% (above 0%: growing) 66.14% (476.54%) Compare
ITOC iTonic Holdings Ltd. $12.4M — — — — — — — Compare
PAVM PAVmed Inc. $12.4M — (loss-making) — (loss-making) +450.00% (above 0%: growing) n/m −125.63% (below 0%: shrinking) (269.70%) (21,278.79%)
MODD Modular Medical, Inc. $12.2M — (loss-making) — — n/m −5.61% (below 0%: shrinking) 0.00% 0.00% Compare
IRIX IRIDEX Corporation $11.9M — (loss-making) — (loss-making) −7.41% (below 0%: shrinking) n/m +130.24% (above 0%: growing) 34.19% (8.19%) Compare
SINT SINTX TECHNOLOGIES, INC. $11.5M — (loss-making) — (loss-making) +952.88% (above 0%: growing) n/m +47.37% (above 0%: growing) 62.19% (74.66%) Compare
BTCY Biotricity Inc. $10.9M — (loss-making) — (loss-making) +10.40% (above 0%: growing) n/m +235.83% (above 0%: growing) 82.55% 3.70% Compare
Median of peers $12.3M — — +10.40% — +47.33% 61.90% (8.19%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 30 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 1.03m 992.47k 3.00
2024 1.37m 798.31k 2.00
2023 953.20k 882.53k 11.00

Ownership

Directors and executive officers, together 13.40%
Tasso Partners, LLC and affiliates 13.40%
Scopia Holdings LLC and affiliates 9.90%
Two Seas Global (Master) Fund LP 9.90%
Greenleaf Partners Fund, LP and affiliates 8.50%
David S. Nagelberg 7.50%
Ayrton Capital LLC 6.90%
Craig Kallman 5.30%
Lishan Aklog, M.D. 5.10%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

PAVmed Inc. (PAVM) Latest News

29 Oct

Impact 3 · · PR Newswire

22 Oct

Impact 4 · · PR Newswire

22 Sep

Impact 4 · · PR Newswire

14 Aug

Impact 3 · · The Motley Fool transcript
Impact 3 · transcript
Impact 3 · · Moby transcript

13 Aug

Impact 3 ·

5 Aug

Impact 4 ·

1 Jun

Impact 3 · · Simply Wall St.

16 May

Impact 4 · · Moby transcript

15 May

Impact 4 · · GuruFocus.com transcript
Impact 4 · · The Motley Fool transcript
Impact 3 · · PR Newswire

14 May

Impact 4 · · Zacks
Impact 3 · · PR Newswire

8 May

Impact 3 · · Zacks

27 Apr

Impact 4 · · Simply Wall St.

24 Apr

Impact 4 · · PR Newswire

23 Apr

Impact 4 · · PR Newswire

8 Apr

Impact 4 · · Simply Wall St.

7 Apr

Impact 4 · · Zacks

2 Apr

Impact 4 ·

31 Mar

Impact 3 · · Moby

30 Mar

Impact 4 ·
Impact 4 · · Zacks
Impact 3 · · PR Newswire

26 Mar

Impact 4 · · PR Newswire

4 Feb

Impact 4 · · PR Newswire

21 Jan

Impact 4 · · PR Newswire
Impact 3 · · Associated Press Finance
stockrow.com/PAVM · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com